ArticleInternational journal of general medicine2026
Effects of Blood Pressure and Antihypertensive Drugs on Rheumatoid Arthritis: A Mendelian Randomization, Network Pharmacology, and Experimental Validation.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We conducted a Mendelian randomization study in conjunction with a network pharmacology study to provide an analytical elucidation of the potential causal relationship between blood pressure and antihypertensive drugs and rheumatoid arthritis. Methods: First, a Mendelian randomization analysis was performed using large-scale GWAS data to assess the causal associations of systolic/diastolic blood pressure and 12 antihypertensive drug classes with rheumatoid arthritis. The analytical model of inverse variance weighting was primarily utilized. Second, we constructed a "drug-component-target-disease" regulatory network graph and analyzed Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment. Third, we validated some of the mined data through molecular docking technology using BIOVIA Discovery Studio 2019. Finally, animal experiments were performed to verify. Results: The results indicated that elevated diastolic blood pressure was significantly associated with an increased risk of rheumatoid arthritis. Among antihypertensive drugs, adrenergic neuron blockers, central antihypertensives, and potassium-sparing diuretics/aldosterone antagonists reduced the risk of rheumatoid arthritis. Sensitivity analyses demonstrated the absence of pleiotropy or heterogeneity. In addition, after network pharmacology research, the molecular docking of its active ingredients with their targets was carried out, and the link potential was relatively ideal. Construction of a rat model of rheumatoid arthritis, Western blotting assay for Endothelin Receptor Type B (EDNRB), Angiotensin II Receptor Type (AGTR) expression level. Western blot analysis showed elevated EDNRB and AGTR levels in the model group, with spironolactone group significantly reducing these levels, though still higher than methotrexate group. Conclusion: The findings of our study indicate that elevated diastolic blood pressure is associated with an increased risk of rheumatoid arthritis. However, three classes of antihypertensive medications, namely adrenergic neuron blockers, central antihypertensives, and potassium-sparing diuretics and aldosterone antagonists, have been demonstrated to exert beneficial effects on rheumatoid arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.